Company intelligence / Profile preview

Curegenix

Burlingame, California, United Statescuregenix.org ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Curegenix is developing small molecule inhibitors targeting the Wnt signaling pathway for oncology and fibrosis indications. Their most advanced programs are in preclinical or IND-enabling stages. The company has filed patents on liposomal formulations for Wnt pathway inhibitor delivery but has not reported clinical results yet.

Therapeutic areas: OtherOncology
Modalities: Small moleculeLiposome-based drug delivery
Industry: Biotech

Drug pipeline

1 asset

CGX1321

Partnerships

None publicly disclosed as of latest available data.

Beyond the preview

Go deeper on Curegenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curegenix.

Explore the full profile